Podcast appearances and mentions of ezra cohen

In this gripping and deeply analytical episode of Devolution Power Hour, Chris Paul and Ghost dissect the latest psychological and narrative warfare shaping global events and the future of America First. The show kicks off with a deep dive into the updated White House COVID-19 origin page, which now points to a lab leak as the source of the virus. But Chris and Ghost aren't buying the limited hangout. Instead, they argue this half-measure narrative protects the deeper truth, that the pandemic was scripted, gamed out, and used as a tool of global subjugation. They explore how information warfare itself is being weaponized, not just to wake up the normies, but to dismantle deep state operatives behind the scenes. General Flynn's fiery post calling out Pam Bondi and Kash Patel for inaction becomes a lightning rod for a larger discussion on loyalty, strategy, and narrative pacing. The hosts break down why we must demand accountability now, not after the midterms, not after 2028, and why friction, conflict, and discomfort are necessary ingredients for justice and real reform. Also in the mix: Trump's evolving Fed strategy, Elon Musk's power struggles inside the administration, the return of Derek Harvey to the National Security Council, and potential signals about Ezra Cohen's next move. From Easter truces to economic proxy wars, and from controlled opposition to 5D chess, this episode is loaded with pattern recognition, game theory, and unapologetic truth-seeking.

On today's episode of Mastering E-commerce Marketing, host Eitan Koter meets up with Ezra Cohen, an e-commerce strategist who helps brands sell more effectively online through channels like Amazon, Walmart, TikTok, and their own websites. Ezra shares what's really working right now in social commerce—especially why TikTok Shop has become such a big deal with younger customers. He also covers how to succeed with subscription services, offering clear tips on making them attractive to customers and profitable for businesses.Ezra and Eitan also talk about the importance of sustainability and how brands can use eco-friendly practices to build trust with shoppers. Plus, Ezra gives useful tips on improving mobile shopping experiences and highlights common mistakes to avoid when launching new products online.Website: https://www.vimmi.net Email us: info@vimmi.net Podcast website: https://vimmi.net/mastering-ecommerce-marketing/ Talk to us on Social:Eitan Koter's LinkedIn: https://www.linkedin.com/in/eitankoter/ Vimmi LinkedIn: https://il.linkedin.com/company/vimmi YouTube: https://www.youtube.com/@VimmiCommunications Guest: Ezra Cohen, eCommerce Representative at ColavitaEzra Cohen's LinkedIn: https://www.linkedin.com/in/ezra-c-4833217bColavita USA: https://colavitastore.com/ Watch the full Youtube video here:https://youtu.be/UAvi6gZSSlgTakeaways:Social commerce is becoming essential for brands to reach consumers where they spend their time.TikTok Shop is a significant player in the social commerce space, especially among Gen Z.Subscription models provide predictable revenue and enhance customer loyalty.Sustainability is increasingly important to consumers and can influence purchasing decisions.Mobile commerce is growing rapidly, with mobile devices accounting for a large portion of online sales.Voice commerce is transforming how consumers shop for everyday necessities.Augmented reality enhances the online shopping experience by allowing consumers to visualize products in their environment.Brands must optimize their websites for mobile to meet consumer expectations.Understanding customer preferences is crucial for successful subscription services.Testing and adapting products based on consumer feedback is vital for long-term success.Chapters:00:00 The Rise of Social Commerce05:46 Subscription-Based E-Commerce Models09:52 The Importance of Sustainability in E-Commerce15:07 The Growth of Mobile Commerce20:50 Transformative Voice Commerce23:32 Augmented Reality in Online Shopping26:04 Navigating Marketplaces: Amazon and Walmart27:33 Lessons Learned and Best Practices

On this important show, Monica discusses the ultimate stakes involved in the election: saving America from the tyranny of weaponized government. This is a dirty job, and only President Trump - fry cook and garbage man - can do it. Monica discusses the final phase of the campaign with strategist/pollster Doug Schoen, and gets a critically important warning about the dangers of the security state from former counterintelligence expert Ezra Cohen. A must-hear!

On this important show, Monica discusses the ultimate stakes involved in the election: saving America from the tyranny of weaponized government. This is a dirty job, and only President Trump - fry cook and garbage man - can do it. Monica discusses the final phase of the campaign with strategist/pollster Doug Schoen, and gets a critically important warning about the dangers of the security state from former counterintelligence expert Ezra Cohen. A must-hear!

Watch The X22 Report On Video No videos found Click On Picture To See Larger Picture The numbers are in, the Fed is now letting everyone know the inflation is coming down and the Fed is now prepping to cut the rates. Bank of America is now predicting 3000 gold. Bolivia has not removed the ban for Bitcoin. The [DS] is structure is being dismantled right before our eyes. The SC has been reversing what the [DS] had in place for a long time. [BO] plan to expose Biden has worked, the fake news was given permission to attack him. The narrative of a change change of batter is now being pushed. Now the media will continue to push every step of the way and they will try to force him out. 25th on deck. Ezra Cohen sends out a warning.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy Federal Reserve's preferred inflation gauge shows price pressures easing further  A measure of prices that is closely tracked by the Federal Reserve suggests that inflation pressures in the U.S. economy are continuing to ease. Friday's Commerce Department report showed that consumer prices were flat from April to May, the mildest such performance in more than four years. Measured from a year earlier, prices rose 2.6% last month, slightly less than in April. Excluding volatile food and energy prices, so-called core inflation rose 0.1% from April to May and 2.6% from 12 months earlier. Both figures were slight improvements on the previous month's data.  Rate cuts by the Fed, which most economists think could start in September, would lead eventually to lower borrowing rates for consumers and businesses. Source: apnews.com https://twitter.com/GRDecter/status/1806731303460733192   - Sticking with a bearish view in 2023 as the benchmark soared 24% The stock market is not the economy. Never forget. Bank of America Eyeballs $3,000 Gold Bank of America is eyeballing $3,000 gold. According to a report released by the big bank, gold prices could potentially hit $3,000 an ounce in the next 12 to 18 months as the Federal Reserve begins cutting interest rates and rising debt drives economic uncertainty. BofA commodity strategist Michael Widmer said he thinks the next bull run will be contingent on a pickup in investment demand. “If non-commercial demand picks up from current levels on the back of the Fed rate cut, the yellow metal could push higher again.” Source: goldseek.com https://twitter.com/BitcoinMagazine/status/1806677713417113859 Political/Rights BREAKING: Chevron is Gone — SCOTUS Rules Unelected Bureaucrats Do Not Have the Power to Create Laws  In a landmark decision, the Supreme Court has overturned the long-standing Chevron doctrine, fundamentally altering the balance of power between the judiciary and federal agencies. The ruling, which came in the case of Loper Bright Enterprises et al. v. Raimondo, Secretary of Commerce, et al., marks a significant shift in the balance of power between the branches of government. The Chevron doctrine, established in the 1984 case Chevron U.S.A. Inc. v. Natural Resources Defense Council, has long been a source of contention. It granted deference to federal agencies in interpreting ambiguous statutes, effectively allowing unelected bureaucrats to make laws through their regulatory actions. However, by a 6-3 majority, the SCOTUS has now declared that such power is unconstitutional and goes against the principles of democratic governance. “Justice Neil Gorsuch, the son of a former Environmental Protection Agency administrator, wrote separately to call Chevron Deference “a grave anom...

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.    TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center.   You will find our full disclosures in the transcript of this episode.  Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma.  By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel.  So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact.  In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery.   Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants.  It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice.  Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive.  So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients.   In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease.  Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort.  Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease.  In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option.  Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance.  Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years?  Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option.   In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago.  In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go?  Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies.  LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms.  So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be.  I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing.   You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942.  Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much.  Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

In this episode, I was lucky enough to interview Adam Trachtman, Director and Owner of Lucid Circus. Adam's upbringing in Haverford, Pennsylvania, and his formative years at a creative and performing arts high school in Philadelphia laid the groundwork for his journey. With a blend of analytical precision inherited from his mother and a risk-taking spirit from his father, Adam embarked on a bold move to the Czech Republic at just 19 years old, driven by a desire to immerse himself in Europe's cultural tapestry. Upon landing in Prague, Adam's entrepreneurial instincts kicked in as he cofounded Lucid Circus with Ezra Cohen, their parallel paths converging from Philadelphia to Prague. Amid the dot-com bubble burst, they smartly combined their firms, blending design and development talents to overcome hurdles. This synergy enabled them to secure clients like AOL and MTV, setting the stage for Lucid Circus's ascent in the digital realm. Beyond the boardroom, Adam's creative vision finds expression in his graphic novel, "Immersion," a labor of love blending artistry with cutting-edge technology. Leveraging neural style transfer, Adam transforms his experiences into a visually captivating narrative, bridging languages and cultures. With "Immersion" gaining traction internationally, Adam's journey epitomizes the entrepreneurial spirit intertwined with a passion for innovation and storytelling.Step into the vibrant streets of Prague and Join us as we explore the intersection of art and technology with  Adam Trachtman on The First Customer!Guest Info:LucidCircushttp://lucidcircus.comAdam Trachtman's LinkedInhttps://www.linkedin.com/in/adam10/Connect with Jay on LinkedInhttps://www.linkedin.com/in/jayaigner/The First Customer Youtube Channelhttps://www.youtube.com/@thefirstcustomerpodcastThe First Customer podcast websitehttps://www.firstcustomerpodcast.comFollow The First Customer on LinkedInhttp://www.linkedin.com/company/the-first-customer-podcast/

Meet Dr. Ezra Cohen, a medical oncologist and cancer researcher based in San Diego. He is organizing clinical and research studies on various cancers at Tempus. In this episode of the Project Purple Podcast, Ezra explains the scientific reasoning behind different cancers and tumors, and how they respond to treatment methods such as immunotherapy, radiation, and chemotherapy. Additionally, Ezra talks about his groundbreaking artificial intelligence work at Tempus, which aims to make clinical trials more accessible and easier to navigate for patients undergoing cancer treatment. He also discusses how this technology has contributed to researching other cancers like pediatric leukemia and how it is used to study pancreatic cancer. Join us for this informative and insightful episode of the Project Purple Podcast to learn more about the clinical trial matching system Tempus offers, and how it can benefit patients seeking cancer treatment. If you'd like to donate to Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/. If you would like to stay up to date with the latest strides that Tempus has made in the cancer space, or to see the clinical trial available to you, visit: https://www.tempus.com/ To learn more about Project Purple, visit https://www.projectpurple.org/ or follow us on social media at these links: https://www.facebook.com/Run4ProjectPurple https://www.instagram.com/projectpurple/ https://twitter.com/Run4Purple https://www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

Hamas's October 7 attack on Israel was a clear intelligence failure, but for whom and in what ways? Counterbalance co-hosts Mike Doran and Peter Rough are joined by Hudson colleague Ezra Cohen, who, fresh off a trip to Israel, provides his view on what led to the failure of intelligence we now know as October 7. A former Pentagon official, Ezra also outlines how each US administration sets intelligence priorities for the entire intelligence community and how the Biden administration may have changed course from its predecessor's priorities.

EPISODE 91 of JOHNNY ENLOW UNFILTERED. Johnny discusses the latest prophetic intel from the Lord. Do you have a question for Johnny Enlow - concerning the spiritual gift of prophecy? Submit it here and we may select it for an upcoming show: www.johnnyenlowunfiltered.com. You can follow Johnny on www.restore7.org and www.restore7.tv. Thank you for making the always-free Elijah List Ministries possible! Go to elijahstreams.com/give to partner with us. Prefer to donate by mail? Make your check or money order (US Dollars) payable to "ELIJAH LIST MINISTRIES" and mail it to: Elijah List Ministries / Elijah Streams TV 525 2nd Ave SW Suite 629 Albany, OR 97321 USA

Washington, and much of the nation, has been scratching its collective head over the case of Lloyd Austin. The Secretary of Defense was hospitalized with major surgery followed by complications. Yet the White House didn't know for nearly a week. For what might have been going on and what should have, Federal Drive Host Tom Temin spoke with Ezra Cohen, a Hudson Institute adjunct faculty member and former Defense Department and National Security Council official. Learn more about your ad choices. Visit megaphone.fm/adchoices

CME credits: 0.25 Valid until: 22-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/accelerating-evidence-based-care-in-la-scchn/16196/ The emergence of early clinical endpoints compared to the current gold standard of overall survival may change the landscape of how clinical trials are designed as well as how patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are managed. At the forefront of this change are unique small molecule agents that help to overcome the inhibitory influence of tumors on the apoptotic pathway. Join Drs. Ezra Cohen and Susan Yom as they focus on why utilizing early endpoints in clinical trials, and eventually the clinic, may provide therapeutic advantages compared to our current gold standard of overall survival.=

Adam Klein moderated a panel with Jared Abrams, a research associate at Applied Research Laboratories; Ivan Lee, the founder & CEO of Datasaur.ai; Alex Joel, a senior project director and adjunct professor at Washington College of Law, American University; and Ezra Cohen, the former chair of Public Interest Declassification Board and Undersecretary of Defense for Intelligence and Security. The conversation touched on the role of technology in helping to manage classified material and the declassification process, along with how technology has increased the amount of classified material. The panel also discussed how AI could help scholars with research. This conversation was part of a multi-panel event on classification and U.S. democracy.

Frommm Wessssst Philadelphia, Ezra Cohen, raised in Mount Airy, Philadelphia, initially pursued a career in animation inspired by the Dire Straits' video "Money for Nothing." He attended the University of the Arts where he delved into various artistic mediums but found his true passion in metal sculpture, particularly artisanal blacksmithing. However, after graduation, a lack of resources and studio space led him and his friend to shift their focus towards graphic design. They established themselves in Philadelphia and New York for their work in Flash animation, featuring in the Macromedia 5 Flash Bible. However, the dot-com crash led to a significant downsizing of their operations, with Cohen transitioning to remote work and ultimately relocating to Prague in 2004.In Prague, after a considerable period of inactivity, Cohen took on a project for AOL following a mass layoff at the company, leading to a year of intensive work. The successful completion of this project resulted in a shift in his career trajectory. He moved to Olomouc, where he began to transition from Flash to open-source CMSs like WordPress and Drupal. This organically evolved into enterprise-level CMSs, custom software development, and eventually a return to front-end design. Cohen's success in his career, as he asserts, largely stemmed from effective networking, an aspect he continues to utilize extensively in his professional pursuits.On a personal note, around a decade ago, Cohen began focusing on his health in preparation for starting a family. He adopted a regular workout routine, reduced alcohol and coffee intake, and started following a flexitarian diet. Inspired by a documentary about longevity featuring Chris Hemsworth, he also explored various wellness practices such as cold therapy and microdosing. Furthermore, Cohen envisions opening a mega art studio equipped with everything from glassblowing to metalworking tools, designed to serve as a creative space for aspiring artists who lack resources, reflecting his own struggles as a young artist.Connect with Jay on LinkedInhttps://www.linkedin.com/in/jayaigner/The First Customer Youtube Channelhttps://www.youtube.com/@thefirstcustomerpodcastThe First Customer podcast websitehttps://www.firstcustomerpodcast.comFollow The First Customer on LinkedInhttp://www.linkedin.com/company/the-first-customer-podcast/

In this podcast we'll be covering some of the latest updates in immunotherapy for head and neck cancer. Ezra Cohen,... The post Updates in immunotherapy for head and neck cancer appeared first on VJOncology.

In this podcast we'll be covering some of the latest updates in immunotherapy for head and neck cancer. Ezra Cohen,... The post Updates in immunotherapy for head and neck cancer appeared first on VJOncology.

Careful the things you say, cause children are nosy little animals and they will listen.Urban Dictionary defines "childs"  as"a much more entertaining way of saying children"Example:Teenage: "look mom! Them childs are running on our vegetable garden!"Mom: *yells* "Y'all go back to your mommies ya hear!"Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram individually @_williepage_ and @yiannisinesCover art by Ezra Cohen 

I hope you know CPR, because you just took my breath away!What is flirting? Who does it? Who wants it? And who's good at it? Willie and Yianni look deeper at the strange human action that is flirting and whether they are good at it.  Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram individually @_williepage_ and @yiannisinesCover art by Ezra Cohen 

DON'T TREAD ON MEYianni and Willie take a moment to not only touch grass this week but talk about it at length. Discussing what it means to society and each of their own personal relationships with grass. Enjoy!Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram individually @_williepage_ and @yiannisinesCover art by Ezra Cohen 

Mr. Henry Sokolski and Mr. Ezra Cohen will discuss ongoing efforts and recommendations for reforming security classification policy. About the Speakers: Mr. Henry D. Sokolski is the Executive Director of the Nonproliferation Policy Education Center, a Washington-based nonprofit organization founded in 1994 to promote a better understanding of strategic weapons proliferation issues among policymakers, scholars, and the media. He teaches graduate-level classes on nuclear policy in Washington, D.C. He is also a Senior Fellow for Nuclear Security Studies at the University of California at San Diego's School of Global Policy and Strategy. From 1989 to 1993, Sokolski served as the Deputy for Nonproliferation Policy in the Office of the Secretary of Defense, for which he received the Secretary of Defense's Medal for Outstanding Public Service. Prior to this, he worked in the Secretary of Defense's Office of Net Assessment on strategic weapons proliferation issues. In addition to his Executive Branch service, Mr. Sokolski worked on the Hill from 1984 through 1988 as senior military legislative aide to Senate Armed Services Committee member Dan Quayle and from 1982 through 1983 as special assistant on nuclear energy matters to TVA Subcommittee Chairman Senator Gordon J. Humphrey. He also worked as a consultant on nuclear weapons proliferation issues to the Intelligence Community's National Intelligence Council; received a Congressional appointment to the Deutch Proliferation Commission, which completed its report in July 1999; served as a member of the Central Intelligence Agency's Senior Advisory Panel from 1995 to 1996; and was a member of the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism, which operated until 2010. Mr. Sokolski has been a resident fellow at the National Institute for Public Policy, the Heritage Foundation, and the Hoover Institution. He also has taught political science courses at the University of Chicago, Rosary College, Georgetown, and Loyola University. On January 11, 2021, President Donald J. Trump appointed Mr. Ezra Cohen to a three-year term on the PIDB and designated him to serve as Chair for a two-year term that ended on January 10, 2023. Prior to his appointment to the PIDB, Mr. Cohen served in senior leadership positions at the Department of Defense (DoD) and Intelligence Community, most recently as the Acting Under Secretary of Defense for Intelligence and Security and Director for Defense Intelligence, Office of the Director of National Intelligence from November 2020 to January 2021. In this role, he exercised authority, direction, and control over the Defense Intelligence Enterprise and Combat Support Agencies. Additionally, he served as the principal civilian intelligence advisor to the Secretary of Defense on all military intelligence related matters, including signals intelligence, human intelligence, sensitive activities, geospatial intelligence, sensitive reconnaissance, counterintelligence, law enforcement, and security. His previous government positions include Acting Assistant Secretary of Defense for Special Operations and Low-Intensity Conflict (SO/LIC); Principal Deputy Assistance Secretary of Defense for SO/LIC; Deputy Assistant Secretary of Defense for Counter-Narcotics and Global Threats; Special Assistant to the President and Senior Director for Intelligence Programs on the National Security Council; Deputy Defense Intelligence Officer for South Asia at the Defense Intelligence Agency; and as a DoD Operations Officer. Mr. Cohen began his government service as an intern researching 1820's tariff legislation in the Center for Legislative Archives, a part of the National Archives and Record Administration. Mr. Cohen has also worked in the private sector for Oracle Corporation. Mr. Cohen received a Bachelor of Arts degree in History from the University of Pennsylvania.

**This episode contains explicit material**...obviously. So tread with care as Yianni and Willie explore the topic of swear words. Join them as they divulge into its etymology, rank English's most common profanities, and share some personal stories from their childhood surrounding certain curse words.Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram individually @_williepage_ and @yiannisinesCover art by Ezra Cohen 

New season new format!This episode is not about "Fame: The Musical" but rather the concept itself. Join hosts Yianni and Willie as they try to figure out who is an A-List celebrity and what they mean to us.Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram individually @_williepage_ and @yiannisinesCover art by Ezra Cohen 

The new Netflix movie “You People” is a romantic comedy centering around Ezra Cohen, a white Jew, who falls in love with Amira, a black Muslim. Very much in the style of My Big Fat Greek Wedding, or Fiddler on the Roof, there are culture clashes and tension, much of which stems from Amira's dad, played by Eddie Murphy, and Ezra's mom, played by Julia Louis Dryfus.The movie touches on a lot of hot button issues that are very much in the news (or, "the culture"), and much negative feedback in the Jewish community centers around particular lines on scenes. This week, Uri and Rivky ask,  what were the filmmakers trying to achieve with this film, what does this say about American culture and society, and what does it say about the state of Jews in America?

CME credits: 0.25 Valid until: 13-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/recent-advances-and-emerging-approaches-in-the-treatment-of-recurrentmetastatic-scchn-matching-the-patient-to-the-optimal-therapy/14495/ While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.=

Host: Ezra Cohen, MD, FRCPSC, FASCO Guest: Petr Szturz, MD, PhD While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.

You People: Movie Review from the Ray Taylor Show Show topic: In this episode Ray reviews “You People”. You People is a 2023 American romantic comedy film about an interracial couple, Ezra Cohen and Amira Mohammed, who face challenges from their families as they navigate modern love in a world of culture clashes, societal expectations, and generational differences. Directed by Kenya Barris and co-written with Jonah Hill, the film features an ensemble cast including Hill, Lauren London, David Duchovny, Nia Long, Julia Louis-Dreyfus, and Eddie Murphy.JOIN Inspired Disorder +PLUS Today! InspiredDisorder.com/plus Membership Includes:Ray Taylor Show - Full Week Ad Free (Audio+Video)Live Painting ArchiveEarly Access to The Many FacesMember Only Discounts and DealsPodcast Back Catalogue (14 Shows - 618 Episodes)Ray Taylor's Personal BlogCreative WritingAsk Me AnythingDaily Podcast: Ray Taylor Show - InspiredDisorder.com/rts Daily Painting: The Many Faces - InspiredDisorder.com/tmf ALL links: InspiredDisorder.com/linksGenres: Comedy - RomCom

You People: Movie Review from the Ray Taylor Show Show topic: In this episode Ray reviews “You People”. You People is a 2023 American romantic comedy film about an interracial couple, Ezra Cohen and Amira Mohammed, who face challenges from their families as they navigate modern love in a world of culture clashes, societal expectations, and generational differences. Directed by Kenya Barris and co-written with Jonah Hill, the film features an ensemble cast including Hill, Lauren London, David Duchovny, Nia Long, Julia Louis-Dreyfus, and Eddie Murphy.JOIN Inspired Disorder +PLUS Today! InspiredDisorder.com/plus Membership Includes:Ray Taylor Show - Full Week Ad Free (Audio+Video)Live Painting ArchiveEarly Access to The Many FacesMember Only Discounts and DealsPodcast Back Catalogue (14 Shows - 618 Episodes)Ray Taylor's Personal BlogCreative WritingAsk Me AnythingDaily Podcast: Ray Taylor Show - InspiredDisorder.com/rts Daily Painting: The Many Faces - InspiredDisorder.com/tmf ALL links: InspiredDisorder.com/linksGenres: Comedy - RomCom

You People is a brand new Netflix Romantic Comedy directed by Kenya Barris. You People is the story of Ezra Cohen played by Jonah Hill. Ezra comes from a Jewish family, his mom Shelley played Julia Louise Dreyfus and dad Arnold played by David Duchovny very much try to set Ezra up with “a nice smart Jewish girl”. Ezra eventually meets Amira played by Lauren London, and THEY hit it off right away. The only problem. Amira comes from a very strong and proud black family, her dad Woody changed his name to Akbar, he is played by Eddie Murphy, her mom is Fatima played by Nia Long. You People is really the story of love, in the middle of a culture clash between these two families. See omnystudio.com/listener for privacy information.

Featuring perspectives from Dr Robert Haddad, including the following topics: ESMO 2022 (0:00) Case: A man in his early 50s presents with metastatic anaplastic thyroid cancer — Ezra Cohen, MD (18:39) Case: A man in his late 60s who has undergone immunotherapy for melanoma is diagnosed with Stage I (cN2 N1) p16-positive squamous cell carcinoma (SCC) of the left tonsil — Erik Rupard, MD (26:21) Case: An Asian woman in her early 40s who has received cisplatin/radiation therapy and gemcitabine/cisplatin for locoregionally advanced nasopharyngeal cancer develops metastatic disease (PD-L1 CPS 10) — Dr Cohen (31:21) Case: A man in his early 70s presents with recurrent and rapidly progressing HPV-negative metastatic head and neck cancer — Neil Morganstein, MD (38:55) Case: A man in his late 50s who has undergone definitive radiation therapy and surgery for locally recurrent SCC of the head and neck presents with worsening shortness of breath — Mamta Choksi, MD (41:42) Case: A man in his early 70s with a longstanding history of T-cell large granular lymphocytic leukemia presents with metastatic HPV-positive SCC of the left nostril (PD-L1-negative) — Spencer H Bachow, MD (44:50) Case: A man in his late 50s presents with HPV-positive Stage III cancer of the base of the tongue — Dr Cohen (49:03) Case: A man in his early 70s presents with metastatic anaplastic thyroid cancer (PD-L1-positive, mutations in TERT promoter, PT53 and MEN1) — Dr Rupard (52:00) Case: A man in his early 60s presents with metastatic papillary thyroid cancer with a BRAF V600E mutation — Dr Cohen (56:16) CME information and select publications

Ezra Cohen is the former Under Secretary of Defense for Intelligence and Security and crafted a memo to protect members of the military and civilian employees of the Department of Defense to keep that from happening. He joins us for this special edition of Just Ask the Question to address a legal concern that potentially affects as many as four million Americans.He is joined by his attorney and frequent guest Mark Zaid to discuss the issue and a September 30 deadline that could make a big difference in the lives of millions of people.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this week's Cyber Report, sponsored by Fortress Information Security, Ezra Cohen, an adjunct senior fellow at the Hudson Institute who served as the acting under secretary of defense for intelligence during the Trump administration, discusses authorities needed to improve national cyber defenses, the logic of separating the National Security Agency and the US Cyber Command, cyber lessons from Russia's war on Ukraine and Chinese operations, role of US government in information warfare, and speeding security clearances with Defense & Aerospace Report Editor Vago Muradian.

Featuring an interview with Dr Ezra Cohen, including the following topics: Spectrum of targetable mutations in thyroid cancer and impact on treatment selection (0:00) Comparative efficacy of TRK inhibitors in patients with thyroid cancer, including those with CNS disease (6:06) Current and emerging roles of immunotherapy alone and in combination with tyrosine kinase inhibitors for patients with head and neck cancer (10:17) Predicting clinical response to immunotherapy for patients with head and neck cancers (19:47) Role of dose reduction in managing toxicities associated with immunotherapy and targeted agents (26:01) Current and potential roles for cell-free DNA testing and minimal residual disease assessment in the management of head and neck cancer (32:08) Recently reported efficacy data with avasopasem in the treatment of radiation-induced oral mucositis (35:27) Factors affecting response to immunotherapy (42:07) CME information and select publications

Featuring a slide presentation and related discussion from Dr Ezra Cohen, including the following topics: Current standard therapy for head and neck cancer (0:00) Emerging data from clinical trials in head and neck cancer (3:41) Current standard therapy and recent research data in thyroid cancer (15:35) CME information and select publications

Dr Ezra Cohen from the Moores Cancer Center at UC San Diego Health in La Jolla, California, discusses key abstracts presented in head, neck and thyroid cancers at the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOHN22).

Featuring a discussion on key abstracts in head, neck and thyroid cancers from the 2022 ASCO annual meeting with Dr Ezra Cohen, moderated by Dr Neil Love.

The Interview: In this episode of Willow Talk, we had the absolute pleasure of chatting with Ezra Cohen. Tackling Ezra's thirteen year music career in one session, we did our best to get as much insight out of this music industry veteran! We chatted about everything from Ezra's earliest days in music (and some questionable middle school fashion choices) to what it's like to be on tour, and why creating meaningful relationships is so important to Ezra (and anyone looking to find their place in their local music scene). We Also Talk About: How Ezra's passion for music first sparked and the people in his life who supported his interest. His impressive 13 year musical career. Why so many of the important lessons we learn in life come from not knowing and simply jumping into the experience. Changing course when you're dealt a new hand - in life and in your career. Ezra's exploration of new facets of the music industry, from singing and songwriting to performing and producing. Balancing your passions with your day job. How Ezra balances songwriting, band practice, and a tour schedule with another full time job. Why hustle doesn't equal success and why we're often happier with our final products when we take the time to slow down and enjoy the process. What it's like to rely on others - friends, family, bandmates, your community - and why it's so important to your growth and making meaningful connections. How a positive mindset = positive energy and why the genuine, positive energy you give out often comes right back to you. Ezra's take on social media and the relationship he's had with the outlet over the years. The comparison trap and the feeling of being genuinely happy for the success of other creatives. Where to Find Ezra: Spotify: Ezra Cohen Bandcamp: Ezra Cohen Instagram: @ezracohen Resources + Other Mentions: Pigeon Pit Molly McDevitt / Small Pond Drift Art House Wanna be first? Sign up for our newsletter to be the first to know about events, updates and the latest news from our artists! More here: Join our Patreon Be featured on our Instagram www.thehouseofwillows.com --- Support this podcast: https://podcasters.spotify.com/pod/show/willow-talk/support

Novel strategies are needed to improve outcomes for patients with LA SCCHN. Enhancing chemoradiation by targeting Inhibitor of Apoptosis Proteins (IAPs) – a class of proteins that regulate apoptosis and modulate immune responses – is currently the most promising strategy, and a phase III clinical trial is underway. Alternative targeted therapies in combination with (chemo)radiation are also being investigated. Dr. Yungan Tao, Dr. Jonathan Schoenfeld, and Dr. Ezra Cohen review the available data for targeting IAPs and consider the future treatment landscape for patients with LA SCCHN. 

Jumping back into another episode, Willie and Yianni discuss a myriad of queer things in this episode including, but certainly not limited to, the Tony Awards and Pride.Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram @derivative.podcast or individually @_williepage_ and @yiannisinesFormerly "New Yorker Issues"Cover art by Ezra Cohen 

On this weeks episode Willie and Yianni discuss their recent relationship troubles and get political with their derivative takes.Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram @derivative.podcast or individually @_williepage_ and @yiannisinesFormerly "New Yorker Issues"Cover art by Ezra Cohen 

Based on improved survival, PD-1 immune checkpoint inhibitors (± chemotherapy) have become the standard of care for patients with recurrent/metastatic SCCHN. However, in patients with locally advanced disease, the results of several clinical trials evaluating the addition of PD-(L)1 inhibitors to conventional chemoradiotherapy have been disappointing. Dr. Ezra Cohen, Dr. Yungan Tao, and Dr. Jonathan Schoenfeld discuss the potential reasons for immunotherapy failure, promising neoadjuvant immunotherapy approaches, and some ongoing, eagerly awaited trials that will hopefully help to define the role of immunotherapy in LA SCCHN.

More than half of patients with head and neck cancer present with locally advanced disease, and high-risk patients continue to have a poor prognosis. The treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is complex and requires a multidisciplinary team approach. Dr. Jonathan Schoenfeld, Dr. Ezra Cohen, and Dr. Yungan Tao discuss the current treatment strategies for these patients and challenges in achieving cure while preserving function and quality of life.

On this weeks episode Willie and Yianni discuss a myriad of topics including the difficulty of writing, how love is dead,  clutter, drag race, and top gun. What a show! And as always the two hosts provide you with their weekly derivative takes.Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram @derivative.podcast or individually @_williepage_ and @yiannisinesFormerly "New Yorker Issues"Cover art by Ezra Cohen 

On this weeks episode Willie calls into the pod on what sounds like a tin can and string, while Yianni experiments with the zoom filters (which has a massive comedic payoff in this audio only medium). As always, the two hosts discuss their derivative takes and also what media they have been consuming.Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram @derivative.podcast or individually @_williepage_ and @yiannisinesFormerly "New Yorker Issues"Cover art by Ezra Cohen 

We're back! After an unscheduled hiatus Willie and Yianni sit down to discuss their time together in Berlin, what they've been consuming, and, of course, their derivative takes.Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram @derivative.podcast or individually @_williepage_ and @yiannisinesFormerly "New Yorker Issues"Cover art by Ezra Cohen 

As we come out from underneath the April skies, here’s our monthly round-up of our 12 most liked indie tracks released in the past few weeks. Featured on this episode is new music by Ezra Cohen, Red Sleeping Beauty, joyride!, and more. Older favourites this month come from Sales and Strawberry Switchblade. Enjoy! Listen to … Continue reading "Indiepop Radio Episode 22-04"

This week there were some scheduling issues which prevented Willie and Yianni recording together; but don't you worry! Yianni has recorded a solo episode where he outlines for Willie some differences between the USA and the UK in preparation for his visit to Ol' Blighty. Plus, as always, Yianni explains his derivative this week. Enjoy!Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram @derivative.podcast or individually @_williepage_ and @yiannisinesFormerly "New Yorker Issues"Cover art by Ezra Cohen 

This week Willie and Yianni are joined by the talented Deana Taheri (@deanapardis) as the first guest to come on to Derivative. There were talks of theatre, style, artists dates and more.365 Days: This Day TrailerDerivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram @derivative.podcast or individually @_williepage_ and @yiannisinesFormerly "New Yorker Issues"Cover art by Ezra Cohen 

This week Willie and Yianni discuss The Oscars (a week late), England vs. America: Who Uses Their Mouth More, Customer Service, the gays, and many other derivative topics.Derivative is a podcast where international hosts Willie and Yianni give hot takes on derivative topics, because what's more derivative than a podcast?Follow us on instagram @derivative.podcast @_williepage_ and @yiannisinesFormerly "New Yorker Issues"Cover art by Ezra Cohen https://ezco.tv/

Ezra Cohen has served, among other roles, in senior intelligence and policy positions in both the White House and the Defense Department. He joins Mike and Marshall to discuss the role of intelligence in the miscalculations that marred the Afghanistan withdrawal, as well as the impact of the withdrawal on America's intelligence capabilities.

The Hake Report, Tuesday, March 2, 2021: Capitol riot fallout continues among the enemies of America. Former DHS head Christopher Miller says Trump called for 10K National Guard troops before Jan. 6th. But turncoat Ezra Cohen-Watnick accuses Trump of throwing America under the bus! GREAT CALLS! Obama and Biden are pushing for "Reparations" for black Americans.  Also check out Hake News from today.  CALLERS Earl from Michigan thinks he's so smart about Trump and the riot. He gets hung up on by James.  Rick from Hampton, VA talks with James about taxes and immorality rising.  Ian from California almost got in a fight with an underage thug at a gas station.  Bobby from Texas has a great call — I believe he's the one who praised Marjorie Green, Josh Hawley, and  Ramon from San Jose, CA is a young man with some sense.  Darryl from Virginia says James and Jesse are the only truth-telling hosts besides Colin Flaherty he knows of.  Art from Ohio gets it off his chest about Earl and other women who support destruction.  Dylan from Nashville, TN — ohh, I think he talked about Alfred Kinsey and the Kinsey Report, which Amazon as well as decent people, should actually ban.  TIME STAMPS 0:00 Tue, Mar 2, 2021 0:45 Dry Bones, Soul-Junk 6:07 Hey, guys!  8:52 Capitol riot fallout 27:43 Earl in MI 37:02 Super Chats 37:45 Rick, Hampton, VA 48:38 BC in NJ 57:49 Violence against Asians 1:02:30 Bring It On, Calibretto 13 1:06:31 Ian in CA 1:22:54 Malcolm X assassination 1:27:07 Ramon, San Jose, CA 1:34:36 Darryl in VA 1:46:35 Art in OH 1:54:51 Dylan, Nashville, TN 1:59:03 Thanks, all! HAKE LINKS VIDEO ARCHIVE: Facebook | Periscope/Twitter | YouTube | Audio podcast links below LIVE VIDEO: Trovo | DLive | Periscope | Facebook | YouTube* | Twitch*  PODCAST: Apple | Podcast Addict | Castbox | Stitcher | Spotify | Amazon | PodBean | Google  SUPPORT: SubscribeStar | Patreon | Teespring | SUPER CHAT: Streamlabs | Trovo   Call in! 888-775-3773, live Monday through Friday 9 AM (Los Angeles) https://thehakereport.com/show  Also see Hake News from JLP's show today.  *NOTE: YouTube and Twitch have both censored James's content on their platforms lately, over fake "Community Guidelines" violations.  BLOG POST: https://www.thehakereport.com/blog/2021/3/2/030221-tue-capitol-riot-rme-mr-q-ezra-cohen-betrayed-trump